Gilead Sciences, Inc. (ETR:GIS)
90.40
-4.16 (-4.40%)
Apr 25, 2025, 5:43 PM CET
Gilead Sciences Revenue
Gilead Sciences had revenue of $6.67B USD in the quarter ending March 31, 2025, a decrease of -0.28%. This brings the company's revenue in the last twelve months to $28.74B, up 4.68% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$28.74B
Revenue Growth
+4.68%
P/S Ratio
4.26
Revenue / Employee
$1.63M
Employees
17,600
Market Cap
113.18B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 21.16B |
Siemens Healthineers AG | 22.67B |
Fresenius SE & Co. KGaA | 21.83B |
Bayer Aktiengesellschaft | 46.61B |
Sartorius Aktiengesellschaft | 3.44B |
Fresenius Medical Care AG | 19.34B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.16B |
Gilead Sciences News
- 2 days ago - Gilead Sciences declares $0.79 dividend - Seeking Alpha
- 2 days ago - Gilead Sciences (GILD) Posts Mixed Q1 2025 Results Amidst Product Dynamics - GuruFocus
- 2 days ago - Gilead sciences highlights potential FDA approval for lenacapavir in June 2025 - Seeking Alpha
- 2 days ago - Gilead Sciences, Inc. (GILD) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Gilead (GILD) Q1 2025 Earnings Call Transcript - The Motley Fool
- 2 days ago - Gilead down 3% after hours as 2025 diluted EPS guidance lowered - Seeking Alpha
- 2 days ago - Gilead Sciences Stock Slips After Mixed Q1 Results, Lowered FY25 EPS Guidance - Benzinga
- 2 days ago - Gilead Sciences in charts: Revenue from HIV product sales grows most among segments in Q1 - Seeking Alpha